Are Ozempic, Wegovy, and other GLP-1 receptor agonists linked to pancreatic cancer risk?

Recent studies have examined whether GLP-1 receptor agonists (GLP-1RAs), including semaglutide (Ozempic, Wegovy), increase pancreatic cancer risk. In this episode, we review the current evidence and how medication safety is assessed in Europe.

In this episode, we cover:

• What GLP-1 receptor agonists are and how they work

• Why pancreatic safety concerns were previously raised

• Findings from recent large observational studies

• The difference between association and causation

• Ongoing pharmacovigilance and regulatory monitoring in the EU

• Known side effects of GLP-1 medicines

• Who may not be suitable candidates for GLP-1 therapy

• Situations where prescription requests may be ...